Morgan Stanley’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-622,650
| Closed | -$15M | – | 7807 |
|
|
2023
Q1 | $15M | Buy |
622,650
+233,944
| +60% | +$2.94M | ﹤0.01% | 2729 |
|
|
2022
Q4 | $4.11M | Buy |
388,706
+3,194
| +0.8% | +$25.8K | ﹤0.01% | 3924 |
|
|
2022
Q3 | $1.74M | Buy |
385,512
+49,605
| +15% | +$226K | ﹤0.01% | 4534 |
|
|
2022
Q2 | $1.34M | Buy |
335,907
+69,585
| +26% | +$330K | ﹤0.01% | 4819 |
|
|
2022
Q1 | $1.95M | Buy |
266,322
+89,163
| +50% | +$533K | ﹤0.01% | 4543 |
|
|
2021
Q4 | $996K | Sell |
177,159
-35,858
| -17% | -$228K | ﹤0.01% | 5067 |
|
|
2021
Q3 | $1.36M | Buy |
213,017
+49,006
| +30% | +$315K | ﹤0.01% | 4849 |
|
|
2021
Q2 | $1.38M | Buy |
164,011
+6,637
| +4% | +$53.6K | ﹤0.01% | 4894 |
|
|
2021
Q1 | $1.65M | Sell |
157,374
-111,928
| -42% | -$1.58M | ﹤0.01% | 4403 |
|
|
2020
Q4 | $4.56M | Buy |
269,302
+208,359
| +342% | +$3.12M | ﹤0.01% | 3359 |
|
|
2020
Q3 | $782K | Buy |
60,943
+27,774
| +84% | +$351K | ﹤0.01% | 4380 |
|
|
2020
Q2 | $468K | Buy |
33,169
+17,449
| +111% | +$220K | ﹤0.01% | 4634 |
|
|
2020
Q1 | $145K | Buy |
15,720
+5,320
| +51% | +$68.6K | ﹤0.01% | 5020 |
|
|
2019
Q4 | $155K | Sell |
10,400
-197,385
| -95% | -$1.76M | ﹤0.01% | 5507 |
|
|
2019
Q3 | $1.42M | Buy |
207,785
+200,010
| +2,572% | +$2.02M | ﹤0.01% | 4071 |
|
|
2019
Q2 | $94K | Buy |
7,775
+7,725
| +15,450% | +$42.1K | ﹤0.01% | 5356 |
|
|
2019
Q1 | $0 | Sell |
50
-1,212
| -96% | -$2.84K | ﹤0.01% | 6769 |
|
|
2018
Q4 | $2K | Buy |
1,262
+728
| +136% | +$2.09K | ﹤0.01% | 6454 |
|
|
2018
Q3 | $2K | Buy |
+534
| New | +$2.11K | ﹤0.01% | 6592 |
|
Other funds holding PRVB
Morgan Stanley's PRVB Position: Q2 2023 in Review
Morgan Stanley sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 622,650 shares — an estimated $15M sold.
Morgan Stanley first reported a position in PRVB in Q3 2018 and held it in 19 quarters. The position peaked at $15M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Morgan Stanley reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Morgan Stanley sold 622,650 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $15M.
- Morgan Stanley first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 19 quarters.
- Morgan Stanley's Provention Bio, Inc. Common Stock position peaked at $15M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.